Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Modulight Biotherapeutics Secures $12.2M Seed Round
SeedVenture Capital

Modulight Biotherapeutics Secures $12.2M Seed Round

•November 12, 2025
•Nov 12, 2025
0

Participants

Modulight

Modulight

company

Nexus NeuroTech

Nexus NeuroTech

investor

Redseed

Redseed

investor

Secret Chord

Secret Chord

investor

Fresh Fund

Fresh Fund

investor

Jibe

Jibe

investor

Saras Capital

Saras Capital

investor

SilverArc

SilverArc

investor

Phoenix Court

Phoenix Court

investor

Axios

Axios

investor

Why It Matters

The capital positions Modulight to advance its first‑in‑class optogenetic therapies, potentially creating a new treatment class for neurological diseases. Success could spur further funding and innovation across the neuro‑tech sector.

Deal Summary

Modulight Biotherapeutics announced the closing of a $12.2 million seed round to fund its optogenetic platform for neurological disorders. The round was led by Jibe Ventures and LocalGlobe, with participation from several other venture firms, accelerating development toward clinical trials.

0

Comments

Want to join the conversation?

Loading comments...